Clinical Professor, Department of Surgery, University of Calgary; Fellowship in Urologic Oncology, MSKCC; Masters in Public Health, Harvard
Calgary, Alberta
Joined April 2013
- Tweets1K
- Following734
- Followers520
- Likes4.3K
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Original Article: Perioperative Apalutamide in High-Risk Localized Prostate Cancer (phase 3 PROTEUS trial) nej.md/3RuNe00
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW
#Oncology #Urology
ALT This image contains four graphs showing the key secondary end points. Graph A shows event-free survival over time in months since randomization comparing ADT plus apalutamide and ADT plus placebo. Graph B presents the first subsequent local or systemic therapy occurrence, with the same treatment comparison. Graph C illustrates distant metastasis or conventional imaging or PSMA PET. Graph D compares freedom from disease at four years with percentages for both treatment groups. Each graph includes shaded confidence intervals and hazard ratios with confidence intervals.
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Tremendous work Dr Taplin @drgotto @DanaFarberNews on this Plenary at #ASCO26. MFS is a meaningful endpoint and patient selection is key. Great discussion from @declangmurphy @gu_onc @OncoAlert
Fantastic discussion by @declangmurphy @PeterMacCC @gu_onc on Proteus trial in high-risk/locally advanced #prostatecancer 👉 PeriOp ADT+apalutamide make the patients’ journey better & do change standard of care in many pts @urotoday @urologysummit @OncoAlert @OpenMedicineHQ
Geoffrey Gotto, MD, MPH, FRCSC retweeted
EMBARK: Overall survival with enzalutamide in biochemically recurrent #ProstateCancer Presented at #ESMO25
cslide.ctimeetingtech.com/es…
Enzalutamide plus leuprolide significantly improves overall survival and delays disease progression compared with leuprolide alone in high-risk biochemically recurrent prostate cancer, supporting it as a standard-of-care option.
@SFreedlandMD
Neal Shore @CURCMB
@drgotto
@RannikkoAntti
@ArnauldVillers
@DrHWoo
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Perioperative enfortumab vedotin + pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: the phase 3 KEYNOTE-905 study. Presented by Christof Vulsteke, MD, PhD. #ESMO25 written coverage by @chavarriagaj @UofT > bit.ly/4olLsJC @myESMO @UroDocAsh
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Real-world experience with darolutamide in 799 patients with #nmCRPC: a prespecified interim analysis of the #DAROL prospective observational study. Presented by Murilo de Almeida Luz, MD. #ESMO25 written coverage by @zklaassen_md > bit.ly/4ngXljc @myESMO
Geoffrey Gotto, MD, MPH, FRCSC retweeted
💫🌟Niraparib + Abiraterone + Prednisone in HRR-deficient mCSPC.🌟💫 nature.com/articles/s41591-0… @AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine @PCF_Science @sloan_kettering
@OncoAlert
💥 First Phase III evidence of PARP inhibition in mCSPC!
🔹 Design: Double-blind, randomized (n=696), HRR+ (56% BRCA1/2)
🔹 Primary endpoint met:
• rPFS HR 0.52 (BRCA) → NE vs 26 mo
• rPFS HR 0.63 (ITT) → NE vs 29.5 mo
🔹 Time to symptomatic progression HR 0.50
🔹 OS (immature): HR 0.79, trend favoring niraparib
🔹 Toxicities: Anemia 29%, Hypertension 27%, manageable
🔹 HRR testing now essential at mCSPC diagnosis
🧠 Clinical impact:
Niraparib + Abiraterone delivers significant PFS improvement in BRCA1/2 mCSPC—marking the PARPi era’s entry into hormone-sensitive disease.
@myESMO @ASCO @UroToday @NatureMedicine @Uromigos
#ProstateCancer #mCSPC #HRR #PARPi #Niraparib #PrecisionOncology #GUOnc #OncoTwitter
Geoffrey Gotto, MD, MPH, FRCSC retweeted
🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj @PCFnews @OncoAlert @urotoday
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Third interim analysis of the DARolutamide ObservationaL #DAROL study in patients with #nmCRPC. Presentation by @drgotto @UCalgary. #AUA24 written coverage by @RKSayyid @UofT > bit.ly/3UEwFwC @AmerUrological
Geoffrey Gotto, MD, MPH, FRCSC retweeted
"Remember that life's most valuable antiques are dear old friends."
@UrologyMSK @doreenchungMD @LonestarUroDoc @drgotto
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Third interim analysis of the DARolutamide ObservationaL #DAROL study in patients with #nmCRPC. Presented by @drgotto @UCalgary. #AUA24 written coverage by @RKSayyid @UofT > bit.ly/3ybNAPe @AmerUrological
Great meeting @pcvblack !
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
Geoffrey Gotto, MD, MPH, FRCSC retweeted
In patients with high-risk biochemically recurrent prostate cancer, treatment with enzalutamide and leuprolide improved metastasis-free survival as compared with leuprolide alone. Read the full results of the EMBARK phase 3 trial): nej.md/402Jenp
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Thank you to @BioAroInc & @AnmolMD for generously donating genomic testing services FREE of charge to 100 eligible patients. This will revolutionize the treatment of metastatic prostate cancer patients!
Excited to see these #EMBARK results presented at #AUA23 Thanks for your leadership @SFreedlandMD and @nealshore
Proud to have co-led the #practicechanging #EMBARK trial with @nealshore showing improved #MFS and trends for better survival for #enzalutamide with or without #ADT. #AUA23 @pfizer @AstellasUS @CSCancerCenter @CedarsSinaiMed
Geoffrey Gotto, MD, MPH, FRCSC retweeted
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive #ProstateCancer. Presentation by @drgotto @saiuCalgary. @ASCO #GU23 written coverage by @WallisCJD @UofT > bit.ly/40ZQz7t
My 99 year-old grandmother died today while protestors danced on the “Tomb of The Unknown Soldier” at our Nation’s capital. Because of their “freedoms”. 😔
Geoffrey Gotto, MD, MPH, FRCSC retweeted
I wrote an op-ed with @UbakaOgbogu on the AMA agreement!: No surprise doctors rejected deal with Alberta government edmontonjournal.com/opinion/…
Geoffrey Gotto, MD, MPH, FRCSC retweeted
The new AB curriculum includes plagiarized passages directly from the internet. @AdrianaLaGrange @JanisIrwin @jkenney @BarbLarochelle @SAndersonshpk
Well done. Not embarrassing at all.
